Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday,...

Nektar to Announce Financial Results for the First Quarter of 2009 on
Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets

SAN CARLOS, Calif., April 29 /PRNewswire-FirstCall/ -- Nektar Therapeutics
(Nasdaq: NKTR) will announce its financial results for the first quarter ended
March 31, 2009 on Wednesday, May 6, 2009, after the close of U.S.-based
financial markets. Howard Robin, president and chief executive officer, will
host a conference call to review the results beginning at 5:00 p.m. Eastern
Time (ET)/2:00 p.m. Pacific Time (PT).

The press release and a live audio-only Webcast of the conference call can be
accessed through a link that is posted on the home page and Investor Relations
section of the Nektar website: http://www.nektar.com. The web broadcast of the
conference call will be available for replay through Wednesday, May 20, 2009.

To access the conference call, follow these instructions:

Dial: (888) 396-2369 (U.S.); (617) 847-8710 (international)
Passcode: 82263149 (Howard Robin is the host)

An audio replay will also be available shortly following the call through
Wednesday, May 20, 2009 and can be accessed by dialing (888) 286-8010 (U.S.);
or (617) 801-6888 (international) with a passcode of 19053055.

In the event that any non-GAAP financial measure is discussed on the
conference call that is not described in the press release, related
information will be made available on the Investor Relations page at the
Nektar website as soon as practical after the conclusion of the conference
call.

About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel
therapeutics based on its advanced polymer conjugation technology platforms.
Nektar's technology and drug development expertise have enabled nine approved
products for partners, which include leading biopharmaceutical companies.
Nektar is also developing a robust pipeline of its own potentially high-value
therapeutics that addresses unmet medical needs by leveraging and expanding
its technology platforms to improve and enable molecules. More information on
Nektar is available at http://www.nektar.com

Jennifer Ruddock, 650-631-4954, Nektar Therapeutics

SOURCE Nektar Therapeutics

Jennifer Ruddock of Nektar Therapeutics, +1-650-631-4954